Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
12 participants
INTERVENTIONAL
2022-12-15
2023-03-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Reliable seizures count is an essential indicator for estimating the care quality and for optimizing treatment. Several studies have highlighted the difficulty for patients to keep a reliable seizure diary due for example to memory loss or perception alterations during crisis. Whatever the reasons, it has been observed that at least 50% of seizures are on average missed by patients.
Seizure detection has been widely developed in recent decades and are generally based on physiological signs monitoring associated with biomarkers search and coupled with detection algorithms. Multimodal approaches, i.e. combining several sensors at the same time, are considered the most promising.
Mobile or wearable non invasive devices, allowing an objective seizures documentation in daily life activities, appear to be of major interest for patients and care givers, in detecting and anticipating seizures occurence.
This single-arm exploratory, multicenter study aims at assessing whether the use of such a non-invasive, wearable device can be useful in a real life setting in detecting seizures occurence through multimodal analysis of various parameters (heart rate, respiratory and accelerometry).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Exploring Patient Impact & Value in Epilepsy Wearables for Seizure Monitoring
NCT06180538
Seizure Detection and Warning System for Epilepsy Patients
NCT01874600
Seizure Detection and Warning System in Epilepsy Patients
NCT02555410
Wearable Devices to Monitor Seizures in Autoimmune Epilepsy
NCT05627661
Severity: Quantifying the Severity of Generalized Tonic-clonic Seizures (GTCS) With Connected Devices
NCT05477121
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Wearable, non invasive sensor for vital signs recording.
All included patients will be provided with a wearable, non invasive sensor for vital signs recording.
Wearable, non invasive sensor for seizure detection
The device consists of a chest strap and an electronics module that attaches to the strap. The device stores and transmits vital sign data including ECG, heart rate, respiration rate, body orientation and activity. This sensor will be worn every day (on a 24 hours basis) excepted during weekends for up to 4 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Wearable, non invasive sensor for seizure detection
The device consists of a chest strap and an electronics module that attaches to the strap. The device stores and transmits vital sign data including ECG, heart rate, respiration rate, body orientation and activity. This sensor will be worn every day (on a 24 hours basis) excepted during weekends for up to 4 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with drug-resistant focal epilepsy
* Patients with high frequency seizures according to investigator's judgement
* Patients that can be followed 4 weeks after inclusion
* Informed consent form signed.
Exclusion Criteria
* Frequent psychogenic non-epileptic seizures
* Pregnant or breastfeeding patients
* Patients displaying sensor contraindications
7 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Reliev Technologies
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Silvia NAPURI, MD
Role: PRINCIPAL_INVESTIGATOR
CHU Rennes
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-A01565-38
Identifier Type: OTHER
Identifier Source: secondary_id
ECEME
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.